LLY Stock Chart & Stats
$20820.85
$112.85(0.54%)
―
--
Day’s Range― - ―
52-Week Range$11,630.00 - $22,700.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)802.00
Market Cap
$19.69T
Enterprise Value$862.11K
Total Cash (Recent Filing)$5.28B
Total Debt (Recent Filing)$43.37B
Price to Earnings (P/E)42.4
Beta0.38
Next Earnings
Aug 05, 2026EPS Estimate
105.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)28.20
Shares Outstanding941,741,400
10 Day Avg. Volume1,300
30 Day Avg. Volume802
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)36.37
Price to Sales (P/S)14.81
P/FCF Ratio107.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$23,652.60Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)616.44
Revenue Forecast (FY)$1.49T
Bulls Say, Bears Say
Bulls Say
Revenue Growth & MarginsSustained, rapid top-line growth alongside material margin expansion demonstrates durable commercial scale across incretins and other franchises. Higher revenue and expanding net margins support long-term reinvestment, manufacturing leverage, and the ability to fund R&D and business development without eroding core profitability.
Cash GenerationMarked improvement in operating and free cash flow versus prior years reflects stronger cash conversion and financial flexibility. Robust cash generation underpins dividends, buybacks, and acquisitive BD, and provides resilience to fund late-stage trials and commercialization even if near-term earnings face headwinds.
Late‑stage Pipeline & BDA deep, diversified late‑stage pipeline plus targeted acquisitions broadens future revenue streams and reduces single‑product dependency. Multiple positive Phase III readouts and active BD expand therapeutic reach, improving the long‑term probability of sustainable growth beyond current blockbuster products.
Bears Say
Elevated LeverageMaterial debt outstanding and above‑average leverage increase financial risk if growth or pricing power softens. Higher indebtedness can constrain capital allocation flexibility, raise interest expense sensitivity to rate moves, and limit optionality for large strategic investments under stressed scenarios.
Regulatory/Pricing RiskA durable, codified Medicare negotiation framework represents a structural downward pressure on prices for selected high‑cost drugs and increases long‑term revenue uncertainty. For a company with large Part D exposure, this can meaningfully compress net realized pricing and margin sustainability over multiple years.
Concentration & Competitive RiskHeavy reliance on incretin franchises and sizable out‑of‑pocket/self‑pay volumes creates vulnerability to generics, new competitors, and shifts in payer coverage. Market concentration around a few products increases the impact of patent expiries, pricing erosion, or coverage restrictions on long‑term revenues.
LLY FAQ
What was Eli Lilly And Company’s price range in the past 12 months?
Eli Lilly And Company lowest stock price was $11630.00 and its highest was $22700.00 in the past 12 months.
What is Eli Lilly And Company’s market cap?
Eli Lilly And Company’s market cap is $19.69T.
When is Eli Lilly And Company’s upcoming earnings report date?
Eli Lilly And Company’s upcoming earnings report date is Aug 05, 2026 which is in 10 days.
How were Eli Lilly And Company’s earnings last quarter?
Eli Lilly And Company released its earnings results on Apr 30, 2026. The company reported $149.701 earnings per share for the quarter, beating the consensus estimate of $122.072 by $27.629.
Is Eli Lilly And Company overvalued?
According to Wall Street analysts Eli Lilly And Company’s price is currently Undervalued.
Does Eli Lilly And Company pay dividends?
Eli Lilly And Company does not currently pay dividends.
What is Eli Lilly And Company’s EPS estimate?
Eli Lilly And Company’s EPS estimate is 105.16.
How many shares outstanding does Eli Lilly And Company have?
Eli Lilly And Company has 941,741,400 shares outstanding.
What happened to Eli Lilly And Company’s price movement after its last earnings report?
Eli Lilly And Company reported an EPS of $149.701 in its last earnings report, beating expectations of $122.072. Following the earnings report the stock price went up 8.978%.
Which hedge fund is a major shareholder of Eli Lilly And Company?
Currently, no hedge funds are holding shares in MX:LLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eli Lilly & Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23,652.60 (― Downside)
$23,652.60 (― Downside)
Blogger Sentiment
Bullish
MX:LLY Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Bullish
Bullish news 65%
Bearish news 35%
Bearish news 35%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.48%
12-Months-Change
Fundamentals
Return on Equity
0.54%
Trailing 12-Months
Asset Growth
30.41%
Trailing 12-Months
Company Description
Eli Lilly And Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
LLY Company Deck
LLY Earnings Call
Q1 2026
0:00 / 0:00
LLY Revenue Breakdown
35.23% Mounjaro
20.78% Zepbound
8.78% Verzenio
35.21% Other products
LLY Stock 12 Month Forecast
Average Price Target
$23,652.60